Evidence map›Paper›PMID 10666368›Full record

ArticleThe American journal of pathology2000

Strong immunostaining for myogenin in rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass.

P Dias, B Chen, B Dilday, H Palmer, H Hosoi, S Singh, C Wu, X Li, J Thompson, D Parham and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of pathology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 190 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Relationships Between HAntioxidants (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Review
  7. We need to talk-how muscle stem cells communicate.Frontiers in cell and developmental biology · 2024
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

P DiasDepartment of Cell Biology, Imgenex Corporation, San Diego, California, USA. pbdias@imgenex.com
B Chen
B Dilday
H Palmer
H Hosoi
S Singh
C Wu
X Li
J Thompson
D Parham
S Qualman
P Houghton
University of Arkansas for Medical Sciences · USSt. Jude Children's Research Hospital · USKyoto Prefectural University of Medicine · JPNationwide Children's Hospital · US

Funding

XENOGRAFT STUDIESP01CA023099 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HOUGHTON, PETER J · 1985 to 2011
$22.4M
MABS TO MYOD FAMILY PROTEINS I MYOGENIC TUMOR DIAGNOSISR44CA060198 · NCI · MEDINOX, INC. · PI DIAS, PETER B · 1997 to 1998
–
NCI NIH HHS 7R 44 CA 60198NCI NIH HHS CA 23099NCI NIH HHS P01 CA023099
6 · The paper itself

Abstract

Rhabdomyosarcomas are a heterogeneous group of tumors with respect to their molecular basis, degree of differentiation, histology, and clinical behavior. Because of the wide variation of tumor morphology, it is often difficult to distinguish between the distinct subtypes of rhabdomyosarcomas. By using cryosections of tumor specimens and immunohistochemistry, in the present study we show that strong expression of myogenin in rhabdomyosarcoma is associated with alveolar histology (P = <0.0001, Fisher's exact test). Although staining for myogenin was observed in 22 of 26 rhabdomyosarcomas, all alveolar rhabdomyosarcomas (nine of nine) showed high levels of staining for myogenin, as defined by the frequency and intensity of staining of the tumor cells. The staining pattern suggests that the tumor cells are clonally derived from myogenin-positive progenitor cells. In contrast, most embryonal rhabdomyosarcomas (13 of 15) were either negative or showed a low level of staining for myogenin. In these tumors a larger proportion of tumor cells were distinctly negative for myogenin. Six of seven alveolar rhabdomyosarcomas that strongly stained for myogenin were also positive for Pax3-7/Forkhead (FKHR) by polymerase chain reaction/reverse transcriptase-polymerase chain reaction. One of two embryonal rhabdomyosarcomas that strongly stained for myogenin was retrospectively found to be positive for Pax3/FKHR transcripts. Quantitative analysis for myogenin by Western blotting using a smaller subset of rhabdomyosarcomas revealed that in general there was a good correlation between immunohistochemical staining and Western blotting (P = 0.01, Pearson Correlation), although the former technique was more sensitive for detecting tumors with low levels of the protein. On average, alveolar rhabdomyosarcomas expressed at least threefold more myogenin than embryonal rhabdomyosarcomas. Our data show that staining for myogenin will be a simple, rapid, and accurate adjunct for distinguishing between alveolar and embryonal rhabdomyosarcomas. We propose that embryonal rhabdomyosarcomas result from an early block in myogenesis, before the expression of myogenin. In contrast, we propose that alveolar rhabdomyosarcomas either originate from a late block in myogenesis (after expression of myogenin) or that the pathological mechanisms involved in these neoplasms also induce strong expression of this protein.

Indexed as

Antibodies, MonoclonalAntibody SpecificityBlotting, WesternChimeraDNA-Binding ProteinsForkhead Box Protein O1Forkhead Transcription FactorsHumansImmunohistochemistryMyogeninPaired Box Transcription FactorsPAX3 Transcription FactorReverse Transcriptase Polymerase Chain ReactionRhabdomyosarcoma, AlveolarStaining and LabelingTranscription FactorsAntibodies, MonoclonalDNA-Binding ProteinsForkhead Box Protein O1Forkhead Transcription FactorsFOXO1 protein, humanMyogeninMYOG protein, humanPaired Box Transcription FactorsPAX3 protein, humanPax3 protein, mousePAX3 Transcription FactorTranscription Factors

Identifiers

PMID10666368
PMCPMC1850049
OpenAlexW2079955251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.